Pharmaceutical companies and other stakeholders are invited to comment on a revised procedure for CADTH’s drug reimbursement review processes (that is, the pan-Canadian Oncology Drug Review, the Common Drug Review, the Interim Plasma Protein Product Review, and the Interim Process for Cell and Gene Therapies).
To help pharmaceutical companies and consultants contribute to the consultation, this webinar will highlight proposed changes that impact industry. Comments shared by industry during the webinar will be included as stakeholder feedback.
See Summary of Proposed Procedures for CADTH Drug Reimbursement Reviews for more details on the consultation.
While the webinar is intended primarily for industry and consultants, other stakeholders are welcome to partake. There is no cost to participate, but registration is required. After registering, you will receive a confirmation email with information about how to join the webinar. Please note that the webinar will be recorded.